Antidepressants, prostaglandins and the prevention and treatment of cancer

Medical Hypotheses

Volumn 69, Issue 3, 2007, Pages 684-689

  Lieb, Julian ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; CHLOROQUINE; CLOMIPRAMINE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE MALEATE; GLYCYRRHIZIC ACID; IBUPROFEN; INDOMETACIN; MONOAMINE OXIDASE INHIBITOR; NEFAZODONE; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PRASTERONE; PROSTAGLANDIN; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; SEROTONIN UPTAKE INHIBITOR; TELOMERASE; TRANYLCYPROMINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CANCER INHIBITION; CANCER PREVENTION; CANCER REGRESSION; CANCER RISK; CARCINOGENESIS; DEPRESSION; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; IMMUNOMODULATION; IMMUNOSTIMULATION; METASTASIS; ONCOGENE; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROSTAGLANDIN SYNTHESIS INHIBITION; RISK FACTOR; VIRUS ACTIVATION;

ANTIDEPRESSIVE AGENTS; ANTINEOPLASTIC AGENTS; BINDING SITES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MODELS, BIOLOGICAL; MODELS, THEORETICAL; NEOPLASMS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PROSTAGLANDINS; TREATMENT OUTCOME;

EID: 34447256154     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.01.036     Document Type: Article

References (82)

1. Williams E.D., Karim S.M.M., and Sandler M. Prostaglandin secretion by medullary carcinoma of the thyroid. Lancet 1 (1968) 22-23
2. Goodwin J.S., Murphy S., Bankhurst A.D., et al. Prostaglandin-producing suppressor cells in Hodgkin's disease. New Engl J Med 297 (1977) 963-968
3. Cohen L.A., and Karmali R.A. Endogenous prostaglandin production by established cultures of neoplastic rat mammary epithelial cells. In Vitro 2 20 (1984) 119-126
4. Bennett A., Berstock D.A., Harris M., Raja B., and Rowe D.J.F. Prostaglandins and their relationship to malignant and benign breast tumors. Adv Prost Thromb Res 4 (1980) 595-600
5. Yang L., Yamagata N., Yadav R., et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Invest 111 5 (2003) 727-735
6. Kokoglu E., Tuter Y., Sandikci K.S., et al. Prostaglandin E2 levels in human brain tumor tissues and arachidonic acid levels in the plasma membrane of human brain tumors. Cancer Lett. 132 1-2 (1998) 17-21
7. Taketo M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (part 1). J Natl Cancer Inst 90 20 (1998) 1529-1536
8. Lieb J. Antidepressants, eicosanoids and the prevention and treatment of cancer. Plefa 65 5-6 (2001) 233-239
9. Chan G., Boyle J.O., Yang E.K., Zhang F., Sacks P.G., et al. Cyclooxygenase-2 expression is up-regulated in squamous cell carcinoma of the head and neck. Cancer Res 59 5 (1999) 991-994
10. Molina M.A., Sitja-Arnau M., Lemoine M.G., Frazier M.L., and Sinicrope F.A. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by non-steroidal anti-inflammatory drugs. Cancer Res 59 17 (1999) 4356-4362
11. Benoit V., Relic B., Leval Xd X., Chariot A., Merville M.P., and Bours V. Regulation of HER-oncogene expression by cyclooxygenase-2 and prostaglandin E2. Oncogene 23 8 (2004) 1631-1635 [Gfeb 26]
12. Mauritz I., Westermayer S., Marian B., Werlach N., Grusch M., and Holzman K. Prostaglandin E (2) stimulates progression related gene expression in early colorectal adenoma cells. Br J Cancer 94 11 (2006) 1718-1725
13. Zaman W., Kaphalia B.S., Ansari G.A., Garofalo R.P., and Casola A. RSV-induced prostaglandin production occurs via cPLA2 activation: role in viral replication. Virology 343 1 (2004) 12-24 [Epub 2005 September 8]
14. Villaneuva A., Garcia C., Paules A.B., et al. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene 17 15 (1998) 1969-1978
15. Munkarah A.R., Morris R., Baumann P., et al. Effects of prostaglandin E2 on proliferation and apoptosis of epithelial ovarian cancer cells. J Soc Gynecol Invest 9 3 (2002) 168-173
16. Ackerman R.C., and Murdoch W.J. Prostaglandin-induced apoptosis of ovarian surface epithelial cells. Prostaglandins 45 5 (1993) 475-485
17. Timoshenko A.V., Xu G., Chakrabarti S., Lala P.K., and Chakraborty C. Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells. Exp Cell Res 289 2 (2003) 265-274
18. Daniel T.O., Liu H., Morrow J.D., Crews B.C., and Marnett L.J. Thromboxane A2 is a mediator of cyclooxygenase dependent endothelial migration and angiogenesis. Cancer Res 59 18 (1999) 4574-4577
19. Onguru O., Kurt B., Ginham O., and Soylemezoglu F. Cyclooxygenase-2 (COX-2) expression and angiogenesis in intracranial ependymomas. Clin Neuropathol 25 5 (2006) 216-220
20. Tisdale M.J. Role of prostaglandins in metastatic dissemination of cancer: minireview on cancer research. Exp Cell Biol 51 (1983) 250-256
21. Dilman V.M. Metabolic Immunodepression that increases the risk of cancer. Lancet December 10 (1977) 1207-1209
22. Baliff B.A., Mincek N.V., and Barratt J.T. Interaction of cyclooxygenases with an apoptosis- and autoimmunity-associated protein. Proc Natl Acad Sci USA 93 (1996) 5544-5549
23. Lonnroth C., Andersson M., and Lundholm K. Indomethacin and telomerase activity in tumor growth retardation. Int J Oncol 18 5 (2001) 929-937
24. Hughes-Fulford M., Wu J., Kato T., et al. Inhibition of DNA synthesis and cell cycle by prostaglandins independent of cyclic AMP. Adv Prost Thromb Leukot Res 15 (1985) 401-404
25. Hughes-Fulford M. Prostaglandin regulation of gene expression and growth in normal and malignant tissues. Adv Exp Med Biol 400A (1997) 269-278
26. Goodlad R.A., Madgwick A.J., Moffatt M.R., et al. Prostaglandins and the dog stomach: Effects of misoprostol on the proportion of mucosa to muscle and on the proportion of different epithelial type cells. Digestion 45 (1990) 212-216
27. Yamaki T., Endoh K., Miyahara I., et al. Prostaglandin E2 activates Src signaling in lung adenocarcinoma cells via EP3. Cancer Lett 214 1 (2004) 115-120
28. Thun M.J., Namboordiri M.M., and Heath Jr. C.W. Aspirin use and reduced risk of fatal colon cancer. New Engl J Med 325 (1991) 1593-1956
29. Harris R.E., Beebe-Donk J., Doss H., and Burr-Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). Oncol Rep 13 4 (2005) 559-583
30. Herrera L.A., Benitez-Bribiesca L., Mohar A., and Ostrosky-Wegman P. Role of infectious diseases in human carcinogenesis. Environ Mol Mutagen 45 2-3 (2005) 284-303
31. Sela O., and Shoenfeld Y. Cancer and autoimmune diseases. Semin Arthritis Rheum 18 (1988) 77-87
32. Isomaki H.A., Hakulinen T., and Joutsenlahti U. Excess risk of lymphomas, leukemia and myeloma in patients with rheumatoid arthritis. J Chronic Dis 31 (1978) 691
33. Grunwald G.B., Klein R., Simmonds M.A., and Kornguth S.E. Autoimmune basis for visual paraneoplastic syndrome in patients with small-cell lung carcinoma. Lancet 1 (1985 23) 658-661
34. Minna J.D., and Bunn Jr. P.A. Paraneoplastic syndromes. In: Devita V.T., et al. (Ed). Principles and practices of oncology (1982), Lippincott, Philadelphia 1476-1517
35. Wang W., Andersson M., Lonnroth C., Svanberg E., and Lundholm K. Anorexia and cachexia in prostaglandin EP1 and EP3 subtype receptor knockout mice bearing a tumor with high intrinsic PGE2 production and prostaglandin related cachexia. J Exp Vclin Cancer Res March (2005)
36. Horton E.W. Actions of prostaglandins E1, E2 and E3 on the central nervous system. Brit J Pharmacol 22 (1964) 189-192
37. Lee R.E. The influence of psychotropic drugs on prostaglandin biosynthesis. Prostaglandins 51 (1974) 63-68
38. Ellis E.F., Rosenblum W.I., and Birkle D.L. Lowering of brain levels of the depressant prostaglandin D2 by the antidepressant tranylcypromine. Biochem Pharmacol 31 (1982) 1783-1784
39. Horrobin D.F., and Manku M.S. Roles of prostaglandins suggested by the prostaglandin agonist/antagonist actions of local anesthetic, antiarrhythmic, anti-malarial, tricyclic antidepressant and methyl xanthine compounds. Effects on membranes and on nucleic acids. Med Hypotheses 3 2 (1977) 71-86
40. Manku M.S., and Horrobin D.F. Chloroquine, quinine, procaine, quinidine, tricyclic antidepressants, and methylxanthines as prostaglandin agonists and antagonists. Lancet 2 7995 (1976) 1115-1117
41. Mak O., and Chen S. Effects of two antidepressant drugs-imipramine and amitriptyline on the enzyme activity of 15-hydroxyprostaglandin dehydrogenase purified from brain, lung, liver and kidney of mouse. Prog Lipid Res 25 (1986) 153-155
42. Ogilvie H. The human heritage (the Ward Jones lecture, Manchester University), Lancet, July 6th, 1957.
43. Penninx B.W., Guralnik J.M., Pahor M., Ferruci L., Cerhan J.R., et al. Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst 90 24 (1998) 1888-1893
44. Frank M., Hendricks S., Johnson D., et al. Antidepressants augment natural killer cell activity: in vivo and in vitro. Neuropsychobiology 39 1 (1999) 18-24
45. Lieb J. Invisible antivirals. Int J Immunopharmacol 16 (1994) 1-5
46. Rosenthal S.H., and Fitch W.P. The antiherpetic effect of phenelzine. J Clin Psychopharmacol 7 (1987) 119
47. Lofft J. MAO inhibitors. Psychiat Times (1985) 11
48. Yeragani Phol M., Keshavan R., et al. Are tricyclic antidepressants effective for aphthous ulcers?. J Clin Psychiat 48 6 (1987) 256
49. Bajwa Z.H., and Ho C.C. Herpetic neuralgia. Use of combination therapy in acute an chronic herpes zoster. Geriatrics 56 12 (2001) 18-24
50. Zilberstein D., and Dwyer D.M. Antidepressants cause lethal disruption of membrane function in the human protozoan parasite Leishmania. Science 226 (1984) 977-979
51. Weinbach E.C., Costa J.L., and Wieder S.C. Antidepressant drugs suppress growth of the human pathogenic protozoan Giardia lamblia. Res Commun Chem Pathol Pharmacol 47 (1985) 145-148
52. Doyle P.S., and Weinbach E.C. The activity of tricyclic antidepressant drugs against Trypanasoma cruzi. Exp Parasitol 68 2 (1989) 230-234
53. Dutta P., Pinto J., and Rivlin R. Antimalarial properties of imipramine and amitriptyline. J Protozool 37 1 (1990) 54-58
54. Bitonti A.J., Sjoerdsma A., McCann P.P., et al. Reversal of chloroquine resistance in malaria parasite Plasmodium falciparum by desipramine. Science 242 (1988) 1301-1303
55. Lass-Florl C., Dierich M., Fuchs D., et al. Antifungal activity against Candid sp. by the serotonin reuptake inhibitor sertraline. Clin Infect Dis 33 12 (2001) E135-E136
56. Lass-Florl C., and Dierich M. Fuchs Antifungal properties of specific serotonin reuptake inhibitors against Aspergillus sp. in vitro. J Antimicrob Chemoth 48 (2001) 775-779
57. Munoz-Bellido, Munoz Criado S., and Garcia-Rodriguez J.A. Antimicrobial activity of psychotropic drugs: selective serotonin reuptake inhibitors. Int J Antimicrob Agent 3 14 (2000) 177
58. Munoz-Bellido J.L., Munoz-Criado S., and Garcia-Rodriguez J.A. In vitro activity of psychiatric drugs against Corynebacterium urealyticum group D2. J Antimicrob Chemoth 37 (1996) 1005-1009
59. Freire-Garabal M., Rey-Mendez M., Garcia-Vallejo L.A., et al. Effects of nefadazone on the development of experimentally induced tumors in stressed rodents. Psychopharmacology (Berl) 176 3-4 (2004) 233-238 [Epub. 2004 May 26]
60. Freire-Garabal M., Nunez M.J., Pereiro D., et al. Effects of fluoxetine on the development of lung metastases induced by operative stress in rats. Life Sci 63 2 (1998) PL31-PL38
61. Arimochi H., and Morita K. Characterization of cytotoxic actions of tricyclic antidepressants on human HT29 colon carcinoma cells. Eur J Pharmacol 541 1-2 (2006) 17-23
62. Xu W., Tamim H., Shapiro S., Stang M.R., and Collet J.P. Use of antidepressants and risk of colorectal cancer: a nested case-control study. Lancet Oncol 7 4 (2006) 301-308
63. Serafeim A., Holder M.J., Grafton G., et al. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 101 8 (2003) 3212-3219 [Epub 2002 December 19]
64. 2+ handling and proliferation in human osteosarcoma cells. Basic Clin Pharmacol Toxicol 95 3 (2004) 124-130
65. Jan C.R., Lu Y.C., Tseng L.L., et al. Effect of the antidepressant desipramine on cytosolic Ca2+) movement and proliferation in human osteosarcoma cells. Pharmacology 69 4 (2003) 190-196
66. Levkovitz Y., Gil-Ad I., Zeidich E., et al. Differential induction of apoptosis by antidepressants in glioma and neuroblastoma cell lines: evidence for p-c-Jun, cytochrome C, and caspase-3 involvement. J Mol Neurosci 27 1 (2005) 29-42
67. Daley E, Wilkie D, Loesch A, Hargreaves IP, Kendall DA, Pilkington GJ, et al. Chloripramine: a novel anticancer agent with a mitochondrial target. Biochem Biophys Res Commun Mar 11;328(2):623-32.
68. Honda T., Favalaro Jr. F.G., Kjanosik T., et al. Efficient synthesis of (-) and (+)-tricyclic compounds with enone functionalities in rings A and C. A novel class of orally active anti-inflammatory and chemopreventive agents. Org Biomol Chem 1 24 (2003) 4384-4391 [Epub 2003 October 31]
69. Myung S.J., Rerko R.M., Yan M., et al. 15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis. Proc Natl Acad Sci USA 103 32 (2006) 12098-12102 8,Epub 2006 Jul 31
70. Jozuka H., Jozuka E., Suzuki M., Takeuchi S., and Takatsu Y. Psycho-neuro-immunological treatment of hepatocellular carcinoma with major depression-a single case report. Curr Med Res Opin 19 1 (2003) 59-63
71. Kimmick G.G., Lovato J., McQuellon E., Robinson E., and Muss H.B. Randomized, double-blind, placebo controlled crossover study of Sertraline (Zoloft) for the treatment of hot flashes in woman with early stage breast cancer taking tamoxifen. Breast J 12 2 (2006) 114-122
72. Durand J.P., Brezault C., and Goldwasser F. Protection against oxaliplatin acute neurosensory toxicity by venlafaxine. Anticancer Drugs i14 6 (2003) 423-425
73. Seymour C.B., Mothersill C., Mooney R., Moriarty M., and Tipton K.F. Monoamine oxidase inhibitors l-deprenyl and clorgyline protect nonmalignant human cells from ionizing radiation and chemotherapy toxicity. Br J Cancer 17 (2003) 89
74. Khouzam H.R., Monteiro A.J., and Gerken M.E. Remission of cancer chemotherapy-induced emesis during antidepressant therapy with nefadazone. Psychoso Med January-February (1998) 60-180
75. Lieb J. Remission of rheumatoid arthritis and other disorders of immunity in patients taking monoamine oxidase inhibitors. Int J Immunopharmacol 5 (1983) 353-357
76. Wernicke J.F., Pritchett Y.L., D'Souza D.N., et al. A randomized controlled study of duloxetine in diabetic peripheral neuropathic pain. Neurology 67 8 (2006) 1411-1420
77. Colleoni M., Mandala M., Perruzotti G., et al. Depression and degree of acceptance of adjuvant cytotoxic drugs. Lancet 356 October 14 (2000) 1326-1327
78. Lieb J. The immunostimulating and antimicrobial properties of lithium and antidepressants. J Infection 49 2 (2004) 88-93
79. Feyerabend P. Against method (1993), Verso, New York
80. Lieb J., and Balter A. Antidepressant tachyphylaxis. Med Hypotheses 15 3 (1984) 279-291
81. Wallace W.A., Balsitis M., and Harrison B.J. Male breast neoplasia with selective serotonin reuptake inhibitor therapy: a report of three cases. Eur J Surg Oncol 4 (2001) 429-431
82. Horrobin D.F. Effective clinical innovation: an ethical imperative. Lancet 359 (2002) 1857-1858